Effect of Metformin Iontophoresis on Knee Osteoarthritis in Postmenopausal Women
Key facts
- Phase
- Phase 3
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 70 years old?
Source: NCT07395895, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Badr University
- Trial code
- NCT07395895
- Record updated
- 9 February 2026
- Original description
This study is designed as a randomized, double-blind, placebo-controlled clinical trial with two parallel groups. All participants will receive a standardized physical therapy rehabilitation program. Participants will be randomly allocated into either a study group receiving metformin iontophoresis or a control group receiving placebo iontophoresis. Both participants and outcome assessors will be blinded to group allocation.Read full original descriptionShow less
Effect of Metformin Iontophoresis Combined With Physical Therapy Rehabilitation on Knee Osteoarthritis in Postmenopausal Women: A Randomized Double-Blind Placebo-Controlled Clinical Trial
This study is designed as a randomized, double-blind, placebo-controlled clinical trial with two parallel groups. All participants will receive a standardized physical therapy rehabilitation program. Participants will be randomly allocated into either a study group receiving metformin iontophoresis or a control group receiving placebo iontophoresis. Both participants and outcome assessors will be blinded to group allocation.
Inclusion: • Postmenopausal women aged 50-70 years; Clinical and radiographic diagnosis of knee osteoarthritis according to the American College of Rheumatology criteria; Radiographic severity classified as Kellgren-Lawrence grade II or III; Chronic knee pain for a duration of at least 3 months; Pain intensity ≥4 on the Visual Analog Scale; Ability to ambulate independently with or without assistive devices; Ability to understand and follow instructions; Willingness to participate and provide written informed consent.
Exclusion: • Severe knee osteoarthritis (Kellgren-Lawrence grade IV); History of knee surgery or intra-articular injections within the previous 6 months; Presence of inflammatory rheumatic diseases such as rheumatoid arthritis or gout; Neurological disorders affecting lower limb function; Uncontrolled metabolic, cardiovascular, or systemic diseases; Current or recent use of metformin or other antidiabetic medications; Skin lesions, infections, or hypersensitivity at the iontophoresis site; Contraindications to electrotherapy such as pacemakers or implanted electronic devices; Body mass index ≥35 kg/m²; Participation in another clinical trial within the last 3 months.